| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/21/2005 | WO2005011607A3 Treatment of cancers expressing p95 erbb2 |
| 07/21/2005 | WO2004113365A3 Hepatitis c serine protease tri-peptide inhibitors |
| 07/21/2005 | WO2004094454A8 Hla-a2 tumor associated antigen peptides and compositions |
| 07/21/2005 | WO2004090109A3 Ccn3 compositions and methods |
| 07/21/2005 | WO2004087059A3 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding |
| 07/21/2005 | WO2004060274A3 Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells |
| 07/21/2005 | WO2004056866A8 Asthma susceptibility locus |
| 07/21/2005 | WO2004030617A3 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| 07/21/2005 | WO2004029197A8 Co-stimulatory molecules |
| 07/21/2005 | WO2004024064A8 Compositions and methods for the diagnosis and treatment of tumor |
| 07/21/2005 | WO2003074005A8 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 07/21/2005 | WO2002000207A9 The controlled release preparation of insulin and its method |
| 07/21/2005 | US20050160483 Glycosaminoglycan deficient proteoglycan expressed in recombinant goat; antiscarring agents and reconstructive/cosmetic surgery |
| 07/21/2005 | US20050159822 Particulate acellular tissue matrix |
| 07/21/2005 | US20050159590 Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| 07/21/2005 | US20050159589 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 07/21/2005 | US20050159586 Linear gamma-carboxyglutamate rich conotoxins |
| 07/21/2005 | US20050159461 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester |
| 07/21/2005 | US20050159460 2-[(1R,3S,4S)-1-benzyl-4-t-butoxycarbonylamino-3-hydroxy-5-phenylpentyl]-5-butyl-thiazole; for inhibiting beta-secretase-mediated cleavage of amyloid precursor protein, particularly to inhibit production of A beta peptide; treatment of diseases associated with a pathological form of A beta peptide |
| 07/21/2005 | US20050159439 Management of postoperative pain |
| 07/21/2005 | US20050159425 Inducing tolerance to an antigen by administering to patient a prostaglandin or agonist thereof, a phosphodiesterase inhibitor, and antigen or a derivative thereof; suppressing immune system or an inflammatory response; for example, use of misoprostol and rolipram; antiinflammatory agents, antiallergens |
| 07/21/2005 | US20050159404 Organic compound |
| 07/21/2005 | US20050159387 Combination of ATP-depleting agents (mitochondrial ATP-inhibitor, a methylthioadenosine phosphorylase inhibitor or an inhibitor of De Novo purine synthesis); chemotherapy |
| 07/21/2005 | US20050159386 Antitumoral composition based on immunogenic polypeptide with modified cell location |
| 07/21/2005 | US20050159385 JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| 07/21/2005 | US20050159384 Human RNase III and compositions and uses thereof |
| 07/21/2005 | US20050159382 For cancer such as prostate cancer |
| 07/21/2005 | US20050159381 Cancer, tumor angiogenesis, diabetic retinopathy, inflammatory conditions such as arthritis, osteoporosis, wound healing |
| 07/21/2005 | US20050159380 used to modulate the expression of Angiopoietin genes |
| 07/21/2005 | US20050159379 RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA) |
| 07/21/2005 | US20050159378 For proliferative diseases and disorders such as multiple drug resistant cancers, such as leukemias including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), Acute lymphocytic leukemia (ALL) , lymphoma, prostate cancer, carcinoma |
| 07/21/2005 | US20050159376 RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| 07/21/2005 | US20050159373 Novel polypeptides, and nucleic acids encoding the same |
| 07/21/2005 | US20050159364 Such as trientine; for treatment of neurodegenerative disorders |
| 07/21/2005 | US20050159363 Selective neuronal nitric oxide synthase inhibitors |
| 07/21/2005 | US20050159362 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| 07/21/2005 | US20050159361 Luteinizing hormone releasing hormone receptor agonist/antagonist (leuprorelin) and steroidal androgen receptor agonist (dehydroepiandrosterone, testosterone); sustained release |
| 07/21/2005 | US20050159360 Improved bioavailability |
| 07/21/2005 | US20050159359 Methods and compositions for derepression of IAP-inhibited caspase |
| 07/21/2005 | US20050159358 polypeptides, multimeric proteins, and polynucleotides of which are for study and regulation of cell and tissue development |
| 07/21/2005 | US20050159357 Treatment of rheumatoid arthritis with soluble Fas-ligand cross-linkers |
| 07/21/2005 | US20050159356 Glucagon-like peptide-1 (GLP-1); for treatment of diabetes, obesity, excessive appetite, insufficient satiety, and metabolic disorders; for converting liver stem/progenitor cells into functional pancreatic cells |
| 07/21/2005 | US20050159355 For treatment of inflammatory diseases |
| 07/21/2005 | US20050159354 Administering agrin fragments which play role in regulating response of central nervous system neurons to excitatory neurotransmitters such as glutamate and nicotine |
| 07/21/2005 | US20050159353 Site-specific preparation of polyethylence glycol-GRF conjugates |
| 07/21/2005 | US20050159352 Use of monocarboxylate transporter protein for thyroid hormone transport |
| 07/21/2005 | US20050159351 polynucleotides that bind to proteins that regulate cell growth and division; used as antitumor agents alone or in combination with known cytotoxic agents |
| 07/21/2005 | US20050159350 Has superagonist properties and is used to stimulate cell division and treat wounds, ischemia, heart disease, neural injuries, peripheral vascular disease, gastric ulcers and duodenal ulcers |
| 07/21/2005 | US20050159349 For treatment of cancer; nontoxic |
| 07/21/2005 | US20050159348 Methods of treatment of periodontal disease |
| 07/21/2005 | US20050159346 Cyclic peptide antitumor agents |
| 07/21/2005 | US20050159345 Such as encephalitis and hepatitis |
| 07/21/2005 | US20050159344 Forming a carboxy-saccharide derivative of the glycopeptide antibiotic that has a substituent containing a dicarboxylic acid in which one of the carboxylic acid groups is coupled with a saccharide |
| 07/21/2005 | US20050159343 Inhibitors of glycosaminoglycans |
| 07/21/2005 | US20050159342 Homogenized vancomycin powder with a quantity of biocompatible carrier, as bactericides for protection against gram-positive bacteria; apply on a cut bone surface for preventing blood loss |
| 07/21/2005 | US20050159341 Scaffolded maleimide clusters for multivalent peptide assembly |
| 07/21/2005 | US20050159340 For treatment or prevent of autoimmune, neurodegenerative and immune hypersensitivity disorders such as Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, allergy, stroke or chronic fatigue syndrome |
| 07/21/2005 | US20050159338 Administering factor XIII systemically or locally optionally in conjunction with activated thrombin. |
| 07/21/2005 | US20050159337 Use of botulinum toxin therapy for treatment of overactive bladder |
| 07/21/2005 | US20050159336 Administering activated lymphocytes; promote nerve regeneration |
| 07/21/2005 | US20050159335 Pharmaceutical administration form for peptides, process for its preparation, and use |
| 07/21/2005 | US20050159334 prophylactic administration; inhibitor has a side chain including a benzamide group to the left and an ester group to the right of a peptide bond; |
| 07/21/2005 | US20050159333 Carbachol, neurokinin A, P2X receptor antagonist, electrical stimulus, to inhibit polypeptide in Rho associated kinase pathway; lower urinary tract disorders, overactive bladder |
| 07/21/2005 | US20050159332 Ntb-a,a a surface molecule involved in natural killer cellss activity |
| 07/21/2005 | US20050158859 Manipulation of non-terminally differentiated cells using the Notch pathway |
| 07/21/2005 | US20050158858 Fibroblast growth factors; endothelial growth factors; gene therapy |
| 07/21/2005 | US20050158832 Secreted glycoprotein hormone fusion for use in regulating the level of red blood cells in circulation |
| 07/21/2005 | US20050158826 Using tumor necrosis factor receptor releasing enzyme as therapeutic tool in treatment of inflammation, arthritis, rheumatoid arthritis and multiple sclerosis |
| 07/21/2005 | US20050158822 Expresion vector comprising nucleotide sequences coding secreted glycoprotein hormone with modified untranslated region for use in enhancement of blood production; directed protein evolution |
| 07/21/2005 | US20050158802 UbcH8 Ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an interferon alpha/beta induced Ubiquitin-like protein |
| 07/21/2005 | US20050158800 Detecting the expression of a G-protein coupled receptor, identifying agonists or antagonists of the receptor |
| 07/21/2005 | US20050158784 Nucleic acids of the human ABCC11 gene, vectors containing such nucleic acids and uses thereof |
| 07/21/2005 | US20050158776 Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof |
| 07/21/2005 | US20050158775 Transgenic animal cell comprising expression vector coding transmembrane/fatty acid synthase fusion for use as model in prevention and treatment of cancer or/an autoimmune disease |
| 07/21/2005 | US20050158771 Using gene expression patterns and skeletal muscle marker as diagnostic tool in detection and prognostication of obesity |
| 07/21/2005 | US20050158760 Interleukin-10 homolog for use as a therapeutic tool in treatment and prevention of inflammatory, autoimmue and cell proliferative disorders |
| 07/21/2005 | US20050158753 Using presence of gastrointestinal system protein (CS141) as diagnostic indcator of gastrointestinal disorders; diagnosing colon and rectum cancer |
| 07/21/2005 | US20050158750 Expression vector comprising nucleotide sequences coding interleukin specific immunoglobulin for use in regulating activation, development, differentiation and function of hematopoietic cells |
| 07/21/2005 | US20050158748 Identification and functional characterization of a novel ribosomal S6 protein kinase |
| 07/21/2005 | US20050158740 Variants of human glycoprotein hormone alpha chain: compositions and uses thereof |
| 07/21/2005 | US20050158735 Double stranded RNA sequences for use in prevention and treatment of restenosis and cell proliferative disorders; gene expression inhibition |
| 07/21/2005 | US20050158727 Derivatized oligonucleotides having improved uptake and other properties |
| 07/21/2005 | US20050158726 Compositons and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 07/21/2005 | US20050158721 Using overexpression of senescence-associated genes as diagnostic/prognostic indicator of organ rejection/failure |
| 07/21/2005 | US20050158719 Polypeptide serving as angiogenic marker and dna thereof |
| 07/21/2005 | US20050158711 viral vector containing a polynucleotide sequence contains two different affinity tag sequences, one of the two affinity tag sequences encodes streptavidin-binding peptide and other encodes calmodulin binding peptide |
| 07/21/2005 | US20050158703 Cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy |
| 07/21/2005 | US20050158397 Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
| 07/21/2005 | US20050158379 Minimization of drug oxidation in drug irradiated excipients formulations |
| 07/21/2005 | US20050158378 contacting liquid comprising solvents, binder and desmopressin acetate, with powders comprising excipients, carriers, diluent or mixtures, within a fluid bed granulation apparatus, selecting air flow, processing temperature and time, then mixing, shearing and compression to tablets; granulation |
| 07/21/2005 | US20050158362 Polymeric, fiber matrix delivery systems for bioactive compounds |
| 07/21/2005 | US20050158356 inhibits scarring that may otherwise occur when the pumps and sensors are implanted; antiscarring agent such as a cell cycle inhibitor |
| 07/21/2005 | US20050158341 Tat and Nef to promote localized accumulation of CD4+ cells, and a compound that stimulates the differentiation of CD4+ ThO cells into either Th1 cells or Th2 cells such as interleukin-4 or an antibody that is capable of binding interferon gamma; treating HIV infections |
| 07/21/2005 | US20050158333 Methods and products related to metabolic interactions in disease |
| 07/21/2005 | US20050158324 Using anti-Beta Casein Like Protein antibodies specific for cancer cells as antiproliferative agents; measuring and comparing BCLP mRNA expression to normal tissue to diagnose colon, breast, lung, ovary, prostate, pancreas or skin cancers; tissue-targeted therapy |
| 07/21/2005 | US20050158319 Pharmaceutical composition containing inhibitors of interferon-gamma |
| 07/21/2005 | US20050158317 Novel proteins with il-6 inhibiting activity |
| 07/21/2005 | US20050158315 Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore |
| 07/21/2005 | US20050158314 For treating chronic immune system disorders, inhibiting rejection of transplanted tissue |
| 07/21/2005 | US20050158311 Via contacting cell with agent that binds Ryk polypeptides, inhibiting signal transduction; for amelioration of cancer |